Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,607 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent 2 Clear all

Conditions: Gastroparesis
Interventions: Gastric Electrical Stimulation (GES) System; Device
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir, Prednisone; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Pirtobrutinib, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HER2 Positive Solid Tumors
Interventions: SBT6050, pembrolizumab, Cemiplimab; Drug
Lead sponsor: Silverback Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more

Conditions: Chronic Hepatitis C
Interventions: Taribavirin, Ribavirin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acne
Interventions: Doxycycline Anhydrous 40 MG, Adapalene/Benzoyl Peroxide Gel 0.3-2.5%; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: Nivolumab, Sitravatinib, Docetaxel; Biological · Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more

Conditions: Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: Onvansertib, Paclitaxel; Drug
Lead sponsor: Antonio Giordano, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: E Cigarette Use, Cessation, Tobacco, Cessation, Nicotine
Interventions: Nicotine Replacement Therapies, Brief Behavioral Counseling; Drug · Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Greenville, North Carolina • Morgantown, West Virginia

Conditions: Obsessive-Compulsive Disorder
Interventions: 3,4-Methyl enedioxy methamphetamine, Methamphetamine, Cognitive Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: Carolyn Rodriguez; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hemostasis
Interventions: Fibrin Pad, SURGICEL™; Drug · Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: Prostatic Neoplasms
Interventions: Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Commack, New York • Harrison, New York • New York, New York + 5 more

Conditions: Hepatitis, HIV/AIDS
Interventions: Boceprevir, Peg-Interferon-alfa 2B, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Rochester, New York

Conditions: Hematological Malignancies
Interventions: Magrolimab, Azacitidine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 26
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 20 more

Conditions: Healthy
Interventions: Shigella sonnei 53G; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 49 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
Interventions: NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion; Drug
Lead sponsor: TyrNovo Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 4 more

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: Acasunlimab, Pembrolizumab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Santa Rosa, California • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Conditions: HIV Infections
Interventions: Interleukin-2 SA, HAART; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 9
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 5 more

Conditions: Multiple Myeloma
Interventions: Oprozomib, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more

Conditions: HER2-positive Early-stage Breast Cancer
Interventions: Trastuzumab, Pertuzumab, Docetaxel, Carboplatin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more

Conditions: Stroke
Interventions: Actuated Virtual Keyboard (AVK) system, Occupational Therapy (OT); Behavioral
Lead sponsor: North Carolina State University; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Interventions: Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine, Stem cell transplant,, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis

Drug Interaction Study Between Dolutegravir and Prednisone

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

The Use of Oracea and Epiduo Forte in Severe Acne Patients

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Onvansertib + Paclitaxel In TNBC

Evaluation of Dependence and Nicotine Replacement Therapy-Supported Cessation Efforts Among Regular Electronic Cigarette Use

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

The Fibrin Patch Soft Tissue Study

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

Finger Movement Training After Stroke

Large Cell Lymphoma Pilot Study III